Caribou Biosciences
CRBU
120 hedge funds and large institutions have $203M invested in Caribou Biosciences in 2022 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 14 closing their positions.
466% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $188K
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
15% more funds holding
Funds holding: 104 → 120 (+16)
5.28% more ownership
Funds ownership: 56.22% → 61.5% (+5.3%)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less capital invested
Capital invested by funds: $313M → $203M (-$110M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.5M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.48M |
| 3 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$8.09M |
| 4 |
BlackRock
New York
|
+$5.59M |
| 5 |
Morgan Stanley
New York
|
+$3.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$4.32M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.74M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.46M |
| 4 |
Alkeon Capital Management
New York
|
-$2.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.23M |
CRBU Hedge Fund Activity: Q2 2022 in Review
120 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2022, worth a combined $203M — down 35% from $313M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CRBU positions and 14 closed out — a net gain of 17 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $12.5M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $4.32M sold.
- 120 institutional investors held Caribou Biosciences (CRBU) as of Q2 2022, up from 104 in Q1 2022.
- Funds reported $203M of Caribou Biosciences stock for Q2 2022, down 35% quarter-over-quarter.
- 31 funds opened new Caribou Biosciences positions in Q2 2022 and 14 closed out, a net change of +17 holders.
- The largest Caribou Biosciences buyer in Q2 2022 was PFM Health Sciences, an estimated $12.5M added.
- The largest Caribou Biosciences seller in Q2 2022 was Monashee Investment Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q2 2022.